A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance

Shengfang Su, Gary Kay, Thomas Hochadel, Jonathan Rojo, J Christopher Stein, Ramesh Boinpally, Antonia Periclou, Shengfang Su, Gary Kay, Thomas Hochadel, Jonathan Rojo, J Christopher Stein, Ramesh Boinpally, Antonia Periclou

Abstract

N-methyl-D-aspartate ionotropic glutamatergic receptor (NMDAR) modulators, including rapastinel and ketamine, elicit rapid and sustained antidepressant responses in patients with treatment-resistant major depressive disorder. This phase I, randomized, multicenter, placebo-controlled, five-period, crossover, single-dose study evaluated simulated driving performance of healthy participants (N = 107) after single doses of rapastinel slow intravenous (i.v.) bolus 900 and 1800 mg, alprazolam oral 0.75 mg (positive control), ketamine i.v. infusion 0.5 mg/kg (clinical comparator), and placebo ~ 45 min before driving. The primary end point was SD of lateral position (SDLP) during the 60-min 100-km simulated driving scenario. Additional measures of driving performance, sleepiness, and cognition were also evaluated. To assess effects over time, mean SDLP was calculated for each 10-min interval of driving. Sensitivity of the assays was confirmed with alprazolam (all placebo comparisons p < 0.02). Rapastinel 900 and 1800 mg did not significantly affect simulated driving performance compared to placebo (both p > 0.5). Both rapastinel doses resulted in significantly less impaired driving compared to alprazolam or ketamine (all p < 0.002); ketamine significantly impaired driving compared to placebo (p = 0.0001). Results for the additional measures were similar to the primary end point. No new safety signals were observed for any study interventions. This first study of rapastinel effects on simulated driving found that rapastinel 900 and 1800 mg did not impair driving performance, but ketamine 0.5 mg/kg resulted in significantly impaired driving performance. Ketamine's effects on driving were maintained for at least 105 min, indicating that clinicians should be vigilant to prevent or postpone driving in patients after ketamine treatment.

Trial registration: ClinicalTrials.gov NCT03814733.

Conflict of interest statement

R.B. is a full‐time employee at AbbVie, Inc. (previously Allergan plc). S.S., J.R., C.S., and A.P. are former full‐time employees at AbbVie, Inc. (previously Allergan plc). T.H. (Chief Executive Officer, Owner) and G.K. (President, Chief Scientific Officer, Owner) of Cognitive Research Corporation and G.K. (Author, Owner) of CogScreen.

© 2021 AbbVie. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

References

    1. Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317:1517.
    1. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM‐5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336‐346.
    1. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155‐162.
    1. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Cur Psychiatr Rep. 2007;9:449‐459.
    1. IsHak WW, Mirocha J, James D, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one‐year follow‐up. Acta Psychiatr Scand. 2015;131:51‐60.
    1. Ionescu DF, Papakostas GI. Experimental medication treatment approaches for depression. Transl Psychiatry. 2017;7:e1068.
    1. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta‐analysis. J Clin Psychiatry. 2005;66:148‐158.
    1. Fava M. Diagnosis and definition of treatment‐resistant depression. Biol Psychiatry. 2003;53:649‐659.
    1. Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N‐methyl‐D‐aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6:97‐114.
    1. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid‐acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Ann Rev Med. 2015;66:509‐523.
    1. Moskal JR, Burch R, Burgdorf JS, et al. GLYX‐13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23:243‐254.
    1. Moskal JR, Burgdorf J, Stanton P, et al. The development of rapastinel (formerly GLYX‐13); a rapid acting and long lasting antidepressant. Cur Neuropharmacol. 2016;14:1‐9.
    1. Giorgetti R, Marcotulli D, Tagliabracci A, Schifano F. Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability. Forensic Sci Int. 2015;252:127‐142.
    1. van de Loo AJAE, Bervoets AC, Mooren L, et al. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on‐road driving performance: a double‐blind, placebo‐controlled study. Psychopharmacology. 2017;234:3175‐3183.
    1. Hayley AC, Green M, Downey LA, et al. The acute and residual effects of escalating, analgesic‐range doses of ketamine on driving performance: a simulator study. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:83‐88.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540‐545.
    1. Posner K, Brown GK, Stanley B, et al. The Columbia‐Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266‐1277.
    1. Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018;38:513‐519.
    1. Kay GG, Horohonich S, Hochadel TJ. CRCDS‐MiniSim: a standardized test for drug impaired driving. ASCP 2018 Annual Meeting (Poster) (2018).
    1. XANAX (alprazolam tablet) Prescribing Information (Pharmacia and Upjohn Company, New York, NY, 2021).
    1. Sinner B, Graf BM. Ketamine. In: Schüttler J, Schwilden H, eds. Modern Anesthetics. Handbook of Experimental Pharmacology. Springer; 2008: 313‐333.
    1. Preskorn S, Macaluso M, Mehra DV, et al. Randomized proof of concept trial of GLYX‐13, an N‐methyl‐D‐aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatric Pract. 2015;21:140‐149.
    1. United States Food and Drug Administration . Evaluating drug effects on the ability to operate a motor vehicle guidance for industry (2017).
    1. Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo‐controlled study. Neuropsychopharmacology. 2002;27:260‐269.
    1. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev. 2004;10:45‐76.
    1. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment‐resistant major depression: a two‐site randomized controlled trial. Am J Psychiatry. 2013;170:1134‐1142.
    1. Louwerens JW, Gloerich ABM, De Vries G, Brookhuis KA, O’Hanlon JF. The relationship between drivers’ blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Noordzij PC, Roszbach R, eds. Alcohol, Drugs and Traffic Safety‐T86. Excerpta Medica; 1987:183‐186.
    1. Kaida K, Takahashi M, Åkerstedt T, et al. Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol. 2006;117:1574‐1581.
    1. Simen A, Gargano C, Cha J‐H, et al. A randomized, crossover, placebo‐controlled clinical trial to assess the sensitivity of the CRCDS Mini‐Sim to the next‐day residual effects of zopiclone. Ther Adv Drug Saf. 2015;6:86‐87.
    1. Kay GG, Schwartz HI, Wingertzahn MA, Jayawardena S, Rosenberg RP. Next‐day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double‐blind, placebo‐controlled, crossover trial. Hum Psychopharmacol. 2016;31:217‐226.
    1. Sun H, MacLeod C, Mostoller K, et al. Early‐stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients. J Clin Pharmacol. 2013;53:1294‐1302.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere